Advances in bone marrow mesenchymal stem cell transplantation for treatment of glaucomatous optic neuropathy
10.3760/cma.j.cn115989-20200302-00131
- VernacularTitle:骨髓间充质干细胞移植治疗青光眼视神经损伤研究进展
- Author:
Shujing WANG
1
;
Zhengbo SHAO
Author Information
1. 哈尔滨医科大学附属第二医院眼科 哈尔滨医科大学心肌缺血教育部重点实验室 哈尔滨医科大学附属第二医院未来医学实验室 150086
- From:
Chinese Journal of Experimental Ophthalmology
2020;38(10):881-884
- CountryChina
- Language:Chinese
-
Abstract:
Glaucoma is a disorder that leads to retinal ganglion cells (RGCs) apoptosis, visual field loss and optic nerve degeneration.The RGCs death is irreversible, which limites their ability for axon regeneration after injury.Bone marrow mesenchymal stem cells (BMSCs) have shown promise as cell-incorporation, cell-supplements and paracrine-mediated therapy for compromised neurons, which have allowed the possibility of the pluripotent BMSCs based regeneration of retinal cells and repair of neurodegenerative diseases.Intravitreal injection, subretinal injection and autologous BMSCs homing transplantation were explored as therapy for various retinal injury conditions.These BMSCs primarily have paracrine trophic effects and can also incorporate into the damaged retina directly, which have regenerative and protective effects on the reduce of RGCs apoptosis and retinal nerve fiber loss, and multiple cell signals and mechanisms are involved.This review provides an update of the current evidence of BMSCs as treatment and potential limitations, and complications for glaucomatous RGCs dysfunction.The researches including induced-differentiation, transplantation methods and the potential neuroprotective mechanism of BMSCs as therapy for glaucomatous retinal degeneration were discussed.
